Piper Sandler Keeps Their Buy Rating on Neurocrine (NBIX)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Neurocrine today and set a price target of $179.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Amsellem is a 4-star analyst with an average return of 6.6% and a 51.30% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Bristol-Myers Squibb.
In addition to Piper Sandler, Neurocrine also received a Buy from TipRanks – Anthropic’s Anthropic Drug Manufacturers – Specialty and Generic in a report issued yesterday. However, on January 8, Morgan Stanley downgraded Neurocrine (NASDAQ: NBIX) to a Hold.
Based on Neurocrine’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $794.9 million and a net profit of $209.5 million. In comparison, last year the company earned a revenue of $622.1 million and had a net profit of $129.8 million
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine’s Ingrezza capsules show efficacy in involuntary movement disorders
- Neurocrine price target lowered to $177 from $179 at JPMorgan
- Neurocrine price target lowered to $169 from $172 at Truist
- Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley
- RBC Capital would be a buyer of Neurocrine on weakness following competitor data
